Literature DB >> 2385570

Effects of biologically active tumour-promoting and non-promoting phorbol esters on in vitro growth of melanocytic cells.

G Brooks1, M Birch, I R Hart.   

Abstract

Sapintoxin A (SAP A), a naturally occurring biologically active but non-promoting phorbol ester, acts as an effective in vitro mitogen for freshly derived human melanocytes. Seven days after addition of 50 nM SAP A there was a four to fivefold increase in melanocyte number over that observed in untreated control cultures comparable to that achieved with a 50 nM concentration of 12-0-tetradecanoylphorbol 13-acetate (TPA). The fluorescent stage 2 promoter sapintoxin D (SAP D) also supported the growth of these cells, with a 50 nM dose producing an increase in cell number comparable to that observed with 200 nM TPA. Similar results were obtained with an established, but non-tumorigenic, line of murine melanocytes. The same compounds exerted a potent anti-proliferative effect against transformed melanocyte lines of murine and human origin associated with morphological alterations and an increase in melanin production consistent with induced cytodifferentiation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2385570     DOI: 10.1111/j.1600-0749.1990.tb00328.x

Source DB:  PubMed          Journal:  Pigment Cell Res        ISSN: 0893-5785


  3 in total

1.  12-O-tetradecanoylphorbol-13-acetate inhibits melanoma growth by inactivation of STAT3 through protein kinase C-activated tyrosine phosphatase(s).

Authors:  Masahiro Oka; Naoko Sumita; Masanobu Sakaguchi; Tetsushi Iwasaki; Toshinori Bito; Toshiro Kageshita; Ken-ichi Sato; Yasuo Fukami; Chikako Nishigori
Journal:  J Biol Chem       Date:  2009-09-15       Impact factor: 5.157

Review 2.  Cell adhesion receptor expression during melanoma progression and metastasis.

Authors:  I R Hart; M Birch; J F Marshall
Journal:  Cancer Metastasis Rev       Date:  1991-06       Impact factor: 9.264

Review 3.  Towards selective pharmacological modulation of protein kinase C--opportunities for the development of novel antineoplastic agents.

Authors:  A Gescher
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.